Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Google Maps has officially renamed the Gulf of Mexico to the Gulf of America. The change came a day after President Donald ...

Eli Lilly reassures investors about strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro. Despite supply chain issues and lower-than-expected sales, the company expects ...

Zepbound is a subcutaneous injection that needs proper storage and handling during travel. There are ways you can travel with Zepbound to ensure it remains safe and effective to use. Zepbound ...

The researchers found that 69,213,936 prescriptions for OMDs were dispensed in the United States during the study period, (HealthDay News) — Prescriptions of obesity management drugs (OMDs) have ...

(CNN) — For 66-year-old Tim Andrews, it was a matter of life or death. Andrews had spent the better part of two years on dialysis because of end-stage kidney disease. He was on the transplant ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.